Fundz

TransCode Therapeutics Announces CFO Departure

PUBLIC · RNAZSep 11, 2026

Position

Chief Financial Officer

Company

TransCode Therapeutics

Thomas A. Fitzgerald, M.B.A.
BostonBiotechnologyHealth CareMedicalTherapeutics

Description

TransCode Therapeutics, Inc. announced the resignation of Thomas A. Fitzgerald as Chief Financial Officer, effective September 9, 2026

Quick answer

TransCode Therapeutics Announces CFO Departure (September 11, 2026). TransCode Therapeutics is based in Boston, Massachusetts, United States.

What did TransCode Therapeutics announce on September 11, 2026?
TransCode Therapeutics, Inc. announced the resignation of Thomas A. Fitzgerald as Chief Financial Officer, effective September 9, 2026
What does TransCode Therapeutics do?
TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics.
Where is TransCode Therapeutics based?
TransCode Therapeutics is based in Boston, Massachusetts, United States.
Which similar companies made leadership changes around the same time?
Novocure (September 9, 2026), Vyome Holdings (September 14, 2026), Abivax (September 7, 2026) and Wave Life Sciences (September 22, 2026) also announced leadership changes within 45 days of TransCode Therapeutics.

Source: Fundz verified event record.

Other recent leadership changes in Medical and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at TransCode Therapeutics, and when

A new leader at TransCode Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day TransCode Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at TransCode Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at TransCode Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

TransCode Therapeutics

Location

Boston, Massachusetts, United States

About

TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its proprietary iron oxide nanoparticle delivery platform, the company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totaling over nine million per year worldwide. Another of the company’s drug candidates, TTX-siPDL1, focuses on treating tumors by targeting a protein called Programmed death-ligand 1 (PD-L1). TransCode also has three cancer-agnostic programs: TTX-RIGA, an RNA–based agonist of the retinoic acid-inducible gene I designed to drive an immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines designed to activate cytotoxic immune responses against tumor cells.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment TransCode Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Zdravka
Senior decision-maker at this company
••••••••@••••••••

See Zdravka's verified email →

Tom
Senior decision-maker at this company
••••••••@••••••••

See Tom's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for TransCode Therapeutics's next move

Learn about Strategic plan

TransCode Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.